<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: <z:hpo ids='HP_0011009'>Acute</z:hpo> <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> rapidly suppresses endogenous <z:chebi fb="105" ids="17234">glucose</z:chebi> production (EGP) in non-diabetic individuals, mainly by inhibiting glycogenolysis </plain></SENT>
<SENT sid="1" pm="."><plain>Loss of this '<z:chebi fb="105" ids="17234">glucose</z:chebi> effectiveness' contributes to fasting <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Elevated NEFA levels characteristic of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> impair <z:chebi fb="105" ids="17234">glucose</z:chebi> effectiveness, although the mechanism is not fully understood </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore we examined the impact of increasing NEFA levels on the ability of <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> to regulate pathways of EGP </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: We performed 4 h 'pancreatic clamp' studies (somatostatin; basal glucagon/growth hormone/insulin) in seven non-diabetic individuals </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="105" ids="17234">Glucose</z:chebi> fluxes (D-[6,6-(2)H(2)]<z:chebi fb="105" ids="17234">glucose</z:chebi>) and hepatic <z:chebi fb="15" ids="28087">glycogen</z:chebi> concentrations ((13)C magnetic resonance spectroscopy) were quantified under three conditions: euglycaemia, <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> with elevated NEFA (HY-NEFA) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: EGP was suppressed by <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, but not by HY-NEFA </plain></SENT>
<SENT sid="7" pm="."><plain>Hepatic <z:chebi fb="15" ids="28087">glycogen</z:chebi> concentration decreased ~14% with prolonged fasting during euglycaemia and increased by ~12% with <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, raising NEFA levels in HY-NEFA caused a substantial ~23% reduction in hepatic <z:chebi fb="15" ids="28087">glycogen</z:chebi> concentration </plain></SENT>
<SENT sid="9" pm="."><plain>Moreover, rates of gluconeogenesis were decreased with <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, but increased with HY-NEFA </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS/INTERPRETATION: Increased NEFA appear to profoundly blunt the ability of <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> to inhibit net glycogenolysis under basal hormonal conditions </plain></SENT>
</text></document>